MOFICEPT

MOFICEPT, Mycophenolate Mofetil also known as MMF is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants.

COMPOSITION:

Mycophenolate Mofetil Tablets 500 mg

MODE OF ACTION:

Mycophenolate Mofetil (MOFICEPT 500) is rapidly absorbed following oral administration and hydrolyzed to form Mycophenolic Acid (MPA). The active metabolite mycophenolic acid prevents T-cell and B-cell proliferation and the production of cytotoxic T-cells and antibodies. Lymphocyte and monocyte adhesion to endothelial cells of blood vessels that normally part of inflammation is prevented via the glycosylation of cell adhesion molecules by MPA. MPA inhibits de novo purine biosynthesis (that promotes immune cell proliferation) by inhibiting inosine 5’-monophosphate dehydrogenase enzyme (IMPDH), with a preferential inhibition of IMPDH II.

INDICATIONS

Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old.

DOSAGE

A dose of 1 g administered orally twice a day (daily dose of 2 g) is recommended for use in adult renal transplant patients. Patients with a body surface area > 1.5 m² may be dosed with MOFICEPT 500 tablets at a dose of 1 g twice daily (2 g daily dose).

STORAGE

Store at room temperature not exceeding 25ᵒC.

DISCLAIMER

This information is for the medical professionals & registered medical practitioners only. This product must be consumed with the valid prescription of registered medical practitioners.